TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Lengthening rate (LR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All-cause death or cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: saliva leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCP patient-centered counseling behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COX-2 inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart rate suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uncorrected binocular near visual acuity (Jaeger value of J3 or better)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance-corrected binocular near visual acuity (0.5 or better)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectacle dependency (never wear glasses)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: dietary outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concern with discoloration of teeth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in L* value from baseline to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in b* value from baseline to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IC (Inspiratory Capacity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: endocardial voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: preservation of renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: global nerve fiber layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rates of graft-versus-host disease
Endpoint domain: Adverse events/effects
Primary endpoint: AMS symptoms reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: events of periodic breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Body-weight-normalized apparent oral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired bladder control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscle spasms and spasticity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of coronary anatomy depiction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ability to detect changes in melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proven fungal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Superficial fungal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Pielou's evenness index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIRS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of tentativeness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of IFN‐γ responses to PPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of IL‐5 responses to PPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: High-frequency band of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-frequency band of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence of Lp 299v on the rectal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: memory and thinking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: overall recovery from stroke
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication discrepancies identified
Endpoint domain: Adverse events/effects
Primary endpoint: Preventable ADEs
Endpoint domain: Adverse events/effects
Primary endpoint: Additional health care expenses prevented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Positive risk factors for iron-deficiency anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive risk factors for TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Speed of Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of Episodic Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Continuity of Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean number of treatment sessions required for endoscopic ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with endoscopic ablation achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time required for the first treatment session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UDI-6 score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIQ-SF7 score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Daytime urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle spasm strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of change in MD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NB(ONH) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NB(fovea) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: palatability of corticosteroid suspensions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: severity of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: EMG produced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of case conferences
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Acceptability score of iron pots
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: calprotectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gait asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KLF4 expression in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean common carotid artery intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effect on CYP enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late postprandial BG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Preventing endoscopic relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reducing frequency and severity of heartburn relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fit accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute left ventricular mass (LVM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LVM indexed to body surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fat-free mass accretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Closure time (CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: chronic low back pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time (RIT) at 5°
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time (RIT) at 12°
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: explosive power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tissue concentration of vancomycin in subcutaneous fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tissue concentration of vancomycin in bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of red man syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: anesthetic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fetal effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: maternal effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: severity of autism symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parental synchronous response to child
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: child initiations with parent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-tau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection rate of hepatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse reactions after vaccinations
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes of atrial fibrillation
Endpoint domain: Adverse events/effects
Primary endpoint: Temporary sinus bradycardia requiring temporary pacing
Endpoint domain: Adverse events/effects
Primary endpoint: COPD exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Discharge resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (ear pain, irritation, bleeding)
Endpoint domain: Adverse events/effects
Primary endpoint: joint score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal ECP and tryptase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time of local tumor control
Endpoint domain: Mortality/survival
Primary endpoint: Change in daily energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GMP-140 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness in treating enuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selective attention and conflict resolution ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of zero blood flow pixels in the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Postcesarean surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in fatal injuries
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in non-fatal injuries
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of stenocardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Discordance between detection techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alteration of the p53 system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1600 m running times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: session attendance in the high-intensity condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in macular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with more than 10 μm of swelling in the central macula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during the first 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time between end of surgery and extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative shivering incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Sodium level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peroperative urine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inhibition of ghrelin-induced growth hormone release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Delayed gastric emptying lag time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total delivered opioid dose
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients requiring opioid treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: enhanced self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: greater social participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: improved problem solving
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Withdrawal for lack of efficacy
Endpoint domain: Adverse events/effects
Primary endpoint: CD4+ lymphocyte count changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum p24 antigen concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tolerability and safety of stavudine
Endpoint domain: Adverse events/effects
Primary endpoint: Achievement of MDA (Minimal Disease Activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events resulting in treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Radiation dose to patients' chest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PNX rate
Endpoint domain: Adverse events/effects
Primary endpoint: Haemoptysis rate
Endpoint domain: Adverse events/effects
Primary endpoint: percent change in Hamilton Rating Scale for Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry eyes symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary CTX‐II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glc‐Gal‐PYD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General health effects of training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General pain disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suckling competence as measured by IBFAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal satisfaction rates
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in 3MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in DSST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to recovery to a train-of-four ratio of 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Centre for Epidemiologic Studies in Depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of common carotid artery IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increase in wall shear stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in negative sexual feelings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deterioration of TrAI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum aminotransferases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lille score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of femoral component positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of outliers for femoral prosthetic alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Activity of daily life improvement (BI scores)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EEG abnormal condition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in E' during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in S' during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV functional reserve indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nosocomial pneumonia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: urinary tract infection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: mean hourly insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Global Efficacy Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: consumption of bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance (CLr) of nemonoxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the plasma concentration‐time curve (AUC0‐∞) of nemonoxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL-mediated cholesterol efflux capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean variation of FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean variation of PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of resolution of psoriatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AST level on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Maximal AST level within 7 postoperative days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Incidence of delayed graft hepatic function
Endpoint domain: Adverse events/effects
Primary endpoint: Corneal perforation or need for therapeutic penetrating keratoplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSCVA at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSA/P detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: clinically relevant serrated polyp detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: improvements in spatiotemporal gait parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall of findings and recommendations
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Compliance with recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: apo CIII levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute radio-epithelitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global efficacy judgement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Contraction-associated heart rate deceleration pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postepidural FHR abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: plasma levels exceeding minimum daily exposure target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Further bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes